Citation: Prachi S, Rishi S (2020) Covid-19... The Dilemmas of a Cardiologist!. J Cardiovasc Med Cardiol 7(2): 097-100. DOI: https://dx.doi.org/10.17352/jcmc.000121

Abstract

The world is witnessing the devastations of SARS-CoV-2 pandemic. It is spreading fast and decimating the society due to high secondary attack rates and high virulence. Patients with known cardiovascular diseases are at an even greater risk of adverse outcomes and mortality by this infection. Also, Covid-19 may present with a multitude of cardiovascular manifestations. This challenges the cardiologists in making the right diagnosis and providing an adequate treatment to these patients, while protecting themselves too from acquiring the infection. Another concern is the dramatic fall in the number of acute coronary syndrome patients reaching the cardiology ER. This makes the patients devoid of the mortality advantage primary percutaneous intervention offers. Lack of definitive treatment and vaccine makes preventive strategy as the most important part while dealing with Covid-19. In this article, the authors summarise the various cardiovascular manifestations of Covid-19 and precautions needed while handling them.

Introduction

Being hit by the third zoonotic corona virus pandemic over the previous few decades, the world is bearing with novel corona virus, SARS-CoV-2. According to WHO’s daily report, as of April 20, 2020, this Corona virus disease 2019 (Covid-19) has affected more than 2.4 million people over 210 countries globally with more than one hundred and sixty thousand deaths. Patients with pre-existing cardiovascular diseases are reported to have the highest mortality [1]. It has been found to have a worse prognosis in patients with chronic medical conditions, hypertension and diabetes. Health care providers need to take adequate precautions to avoid getting infected themselves. In a study, approximately 4% of the Covid-19 affected individuals were health care personnel [1].

Covid-19 with Cardiovascular Presentations

Apart from causing fever, cough and dyspnea, Covid–19 may present with a multitude of cardiovascular manifestations [2]. There have been case reports of patients presenting as Non-ST Segment Elevation Myocardial Infarction (NSTEMI) with non specific ST-T wave changes on electrocardiogram with an elevated troponin levels as well as ST Segment Elevation Myocardial Infarction (STEMI). Many patients present with arrhythmias, cardiomyopathy and pulmonary edema. There is a case report of Covid–19 induced myopericarditis even in the absence of clinically evident pulmonary involvement [3]. Such a presentation may lead to a delay in diagnosis of Covid–19 and a high degree of suspicion is required. 26% of the Covid–19 patients required cardiologic intensive care in a report on 138 patients hospitalised at Zhongnan University Hospital of Wuhan [4]. Of these, 16.7% developed arrhythmias and 7.2% had acute cardiac injury. Although very little is yet known, it is perhaps due to pro-inflammatory state induced by the infection and increased metabolic demands that it leads to such cardiac complications. According to a meta-analysis, biomarker of cardiac injury, troponin I was significantly more in patients with more severe illness [5]. Patients with Covid–19 are at increased risk of venous thromboembolism with elevated D-dimer levels [6].

The Do’s and the Don’ts while Managing Covid-19 Patients

We have all grown up hearing that ‘Prevention is better than cure’. This is the time to understand this locution more
Dilemmas in treatment

While there is no proven therapy or vaccine for this viral disease, preventive measures and supportive management of complications are the sole determinants of its containment. No clinical trial supports the role of any medicine even for prophylactic use. Although chloroquine and hydroxychloroquine have been tried with limited benefit, we need randomised clinical trials to support this. Hydroxychloroquine is known to prolong QTc interval and this effect may be marked when it is given in combination with other QTc prolonging drugs like azithromycin [9]. We need to be more watchful for this side effect as this may precipitate lethal ventricular tachyarrhythmias, especially in elderly, women, concomitant diuretic use, hypokalemia and hypomagnesemia [Table 1] [10]. A Tisdale score of ≤6 predicts low risk, 7–10 medium risk, and >11 high risk of drug-associated QT prolongation [Table 2]. Drugs like ritonavir, lopinavir, oseltamivir, ribavirin have been tried but lack strong evidence [11]. In the absence of clinical trials and conflicting data from in-vitro and animal studies, the use of interferons and corticosteroids also cannot be recommended [11]. Hu, et al. [12] report treating Covid-19 associated fulminant myocarditis with a combination of methylprednisolone (200 mg/day) and immunoglobulin (20 g/day) each for four days. There have been certain reports of using plasmapheresis to deal with the cytokine storm in this illness, but there are no studies to recommend this at present. Remdesivir, a monophosphate produg that undergoes metabolism to an active C–adenosine nucleoside triphosphate analogue is emerging as a promising therapy for the treatment of RNA viruses including this novel corona virus [11].

There have been various social media posts suggesting that ACE inhibitors increase the risk of infection as well as the severity of Covid–19. SARS–CoV–2 enters human cells through binding with its spike protein to angiotensin converting enzyme 2 (ACE2), which is up-regulated by ACE inhibitors [1]. This may explain the phenomenon and we need more concrete data before we can make this recommendation. However, it is not appropriate for us to withhold ACE inhibitors as this may precipitate strokes and heart failure in patients with chronic cardiovascular diseases. Unless we have evidence to the contrary, we need to continue ACE inhibitors in patients with cardiovascular diseases [10].

It is not surprising to have a shortage of adequate personal protective kits during such an unforeseen pandemic. There should be minimum staff at a time. It is acceptable to postpone routine follow up visits and elective procedures [7]. Percutaneous interventions for stable coronary artery disease and procedures for structural heart diseases need to be postponed. It is important to prevent cross contamination as well as to preserve resources.

Telemedicine offers a helpful way to reach out to our patients in such challenging times. This helps prevent exposure of other patients and hospital staff to Covid–19 positive patients. As our patients with established cardiovascular diseases are at maximal risk of serious illness, we need to take utmost care to prevent cross-infection. We need to solve their queries and tell them to refill their prescription medicines without exposing them to the hospital crowd, as far as we can. We need to inform them to take special care of themselves and follow hand hygiene and social distancing. But in developing countries like India, this is very difficult. There is a lack of resources and preparedness to achieve this effectively.
enzyme 2 (ACE2) receptors [13]. This has triggered worry regarding the use of ACE inhibitors and ARBs as these drugs upregulate the ACE2 receptors [14] and may lead to more deleterious effects. Contrary to this, there is some evidence supporting the protective effect of ARB and ARNI (Angiotensin II Receptor–Neprilysin Inhibitor) [15,16]. In view of conflicting data and no evidence of harm, it is currently recommended to continue these drugs in patients already taking them [17].

**Missing STEMI!**

Around the world, the number of acute coronary syndrome patients reaching the emergency room has dramatically fallen. Catheterisation laboratory activation for primary percutaneous coronary intervention of STEMI is reduced by approximately 40% [18,19]. Similarly, the number of patients arriving for other reasons like worsening heart failure has reduced. Perhaps, people are afraid of getting out of their homes and especially visiting a hospital for the fear of catching infection with this corona virus. There are no routine follow up visits anyway due to lockdown, whether imposed by the government or self imposed. When this pandemic shall pass away, may be we will have an increasing number of STEMI who could seek no timely intervention. Lot of them may even face adverse consequences of the same as they are getting deprived of the mortality advantage that primary PCI gives [20].

**Concluding Hopes for Health!**

While the researchers strive to find a vaccine for this virus, let’s keep all precautions to avoid getting infected. Let’s have a stronger will power to work and serve our patients in these adverse circumstances. Let’s be more vigilant to rule out Covid-19 infection among our cardiology ICU patients. We should advice our patients to keep their mind and body occupied in a healthy way during the lockdown period. Exercising indoors and eating a healthy food are essential. Keep your minds occupied with positive ideas to avoid depression in these gloomy times. The doctors and other health care providers also should keep special focus on their health both physical and mental as many are becoming depressed. There’s light at the end of the tunnel!

**References**

1. Wu Z, McGoogan JM (2020) Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 323: 1239-1242. Link: https://bit.ly/3c2YLea
2. Huang C, Wang Y, Li X, Ren L, Zha J, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395. 497-506. Link: https://bit.ly/2Za7ASR
3. Inciardi RM, Lupi L, Zacccone G (2020) Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. Link: https://bit.ly/2ZiX0Zc
4. Wang D, Hu B, Hu C (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323: 1061-1069. Link: https://bit.ly/2Wg8l2g
5. Lippi G, Lavie CJ, Sanschag-Gomar F (2020) Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis. Link: https://bit.ly/35oPJoH
6. Yang X, Yu Y, Xu J (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. Link: https://bit.ly/2KU5TM1
7. Welt FGP, Shah PB, Bortnick AE, Henry TD, et al. (2020) Interventionsal Council and the Society of Cardiovascular Angiography and Intervention (SCAI), Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From ACC’s Interventionsal Council and SCAI, Journal of the American College of Cardiology. Link: https://bit.ly/2SizEcz
8. Han Y, Zeng H, Jiang H, Yang Y, Yuan Z, et al. (2020) CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic. Link: https://bit.ly/2Rxnwih
9. Behr ER, Roden D (2013) Drug-induced arrhythmia: pharmacogenomic prescribing? European Heart Journal 34: 89-95. Link: https://bit.ly/3aUNILp
10. Tisdale JE, Jayes HA, Kingery JR (2013) Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 6: 479-487. Link: https://bit.ly/3ISyNys
11. Sanders JM, Monogue ML, Jodloowski TZ, Cутrell JB (2020) Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. Link: https://bit.ly/2Wk6Q6m
12. Hongde Hu, Fenglian Ma, Wei X, Fang Y (2020) Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. Link: https://bit.ly/2YxIEFc
13. Chen L, Hao G (2020) The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease, Cardiovascular Research, cval993. Link: https://bit.ly/3F6Pxcz
14. Zheng Y, Ma Y, Zhang J (2020) COVID-19 and the cardiovascular system. Nat Rev Cardiol 17: 259-260. Link: https://bit.ly/2S5T2Wq
15. Gurwitz D (2020) Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. Link: https://bit.ly/24LhWdz
16. Acanfora D, Ciccone MM, Scicchitano P, Acanfora C, Casucci G (2020) Neprilysin inhibitor–angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients, European Heart Journal-Cardiovascular Pharmacotherapy, pva028. Link: https://bit.ly/3bZKP3y
17. de Simone G (2020) Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. European Society of Cardiology. Link: https://bit.ly/2zyjnD6
18. Garcia S, Albaghdadi MS, Meraj PM, Schmidt C, Garberich R, et al. (2020) Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic, Journal of the American College of Cardiology. Link: https://bit.ly/2xop7Xy
19. Rodríguez-Leor O (2020) Impact of the COVID-19 pandemic on care activity in patients with severe acute myocardial infarction due to COVID-19 and the cardiovascular system. Eur J Cardiovasc Dis. Link: https://bit.ly/35oPJoh
20. Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of randomized trials. Lancet (London, England). 361: 13-20. Link: https://bit.ly/2VTEULP

Citation: Prachi S, Rishi S (2020) Covid-19.. The Dilemmas of a Cardiologist!. J Cardiovasc Med Cardiol 7(2): 097-100. DOI: https://dx.doi.org/10.17352/2455-2976.000121